|
Quantitative
analysis of mRNA encoding SEREX-defined breast cancer antigens
in normal and malignant breast tissue: Relation between mRNA level
and immunogenicity.
|
Antigen
|
Ratio
of mRNA in breast cancer to mRNA in normal breast in patient
#
(‘+’
indicates serum antibody reactivity1)
|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
102
|
|
BR-41
|
0.01
|
0.19
|
0.04
|
0.26
|
0.38
|
0.11
|
0.10
|
0.86
|
0.03
|
0.07
|
|
BR-45/Kinesin
2
|
0.50
|
0.35
|
0.41
|
0.25
|
0.34
|
0.27
|
0.43
|
0.85
|
0.23
|
0.57
|
|
BR-56/gC1Q
|
0.66
|
0.49
|
0.22
|
0.83
|
0.40
|
0.44
|
0.69
|
0.77
|
0.44
|
3.71
(+)
|
|
BR-57/Her2neu
|
0.30
|
1.17
|
2.48
|
2.18
|
1.43
|
65.49
|
107.39
|
5.91
|
0.44
|
1.81
(+)
|
|
BR-62
|
1.21
|
1.65
|
0.26
|
2.20
|
5.19
|
3.80
|
4.22
|
53.44
|
15.49
|
12.21
(+)
|
|
BR-63/TP
D52
|
1.44
|
4.08
|
0.91
|
7.36
|
6.26
|
2.08
|
2.88
|
132.51
|
1.67
|
5.33
(+)
|
|
BR-75
|
2.27
|
0.34
|
0.48
|
0.59
|
0.43
|
0.34
|
0.37
|
0.78
|
0.36
|
1.06
(+)
|
|
BR-85
|
5.55
|
6.28
|
1.15
|
6.65
|
3.17
|
4.98
|
5.91
|
11.42
|
10.34
|
11.34
(+)
|
|
BR-96
|
0.53
|
1.09
|
0.45
|
0.65
|
0.39
|
0.33
|
0.56
|
0.81
|
0.31
|
1.26
|
|
BR-98/MAGE
D
|
0.16
|
2.10
|
0.58
|
2.55
|
0.73
(+)
|
0.58
|
0.67
(+)
|
12.67
|
1.44
|
0.60
|
1Serum
reactivity of patients # 1, 3, 5, 6, 7, 8, 9, and 10 assessed
in the plaque assay.
2Patient # 10 referred to as allogeneic-1 in Table
1.
|
